Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

被引:331
作者
Verdú, EF
Bercik, P
Verma-Gandhu, M
Huang, XX
Blennerhassett, P
Jackson, W
Mao, Y
Wang, L
Rochat, F
Collins, SM
机构
[1] McMaster Univ, IDRP, Hamilton, ON, Canada
[2] Nestle Res Ctr, Dept Nutr & Hlth, CH-1000 Lausanne, Switzerland
关键词
D O I
10.1136/gut.2005.066100
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aim: Abdominal pain and discomfort are common symptoms in functional disorders and are attributed to visceral hypersensitivity. These symptoms fluctuate over time but the basis for this is unknown. Here we examine the impact of changes in gut flora and gut inflammatory cell activity on visceral sensitivity. Methods: Visceral sensitivity to colorectal distension (CRD)was assessed at intervals in healthy mice for up to 12 weeks, and in mice before and after administration of dexamethasone or non-absorbable antibiotics with or without supplementation with Lactobacillus paracasei (NCC2461). Tissue was obtained for measurement of myeloperoxidase activity (MPO), histology, microbiota analysis, and substance P (SP) immunolabelling. Results: Visceral hypersensitivity developed over time in healthy mice maintained without sterile precautions. This was accompanied by a small increase in MPO activity. Dexamethasone treatment normalised MPO and CRD responses. Antibiotic treatment perturbed gut flora, increased MPO and SP immunoreactivity in the colon, and produced visceral hypersensitivity. Administration of Lactobacillus paracasei in spent culture medium normalised visceral sensitivity and SP immunolabelling, but not intestinal microbiota counts. Conclusion: Perturbations in gut flora and in inflammatory cell activity alter sensory neurotransmitter content in the colon, and result in altered visceral perception. Changes in gut flora may be a basis for the variability of abdominal symptoms observed in functional gastrointestinal disorders and may be prevented by specific probiotic administration.
引用
收藏
页码:182 / 190
页数:9
相关论文
共 40 条
[1]  
Agréus L, 2001, AM J GASTROENTEROL, V96, P2905
[2]   THE ETIOLOGICAL ROLE OF ANTIBIOTIC-PROPHYLAXIS WITH HYSTERECTOMY IN IRRITABLE BOWEL SYNDROME [J].
ALUNJONES, V ;
WILSON, AJ ;
HUNTER, JO ;
ROBINSON, RE .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1984, 5 :S22-S23
[3]   Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial [J].
Atkinson, W ;
Sheldon, TA ;
Shaath, N ;
Whorwell, PJ .
GUT, 2004, 53 (10) :1459-1464
[4]   Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice [J].
Barbara, G ;
De Giorgio, R ;
Deng, YK ;
Vallance, B ;
Blennerhassett, P ;
Collins, SM .
GASTROENTEROLOGY, 2001, 120 (07) :1729-1736
[5]   Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice [J].
Barbara, G ;
Vallance, BA ;
Collins, SM .
GASTROENTEROLOGY, 1997, 113 (04) :1224-1232
[6]  
Barron RP, 2004, J OROFAC PAIN, V18, P62
[7]   Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction [J].
Bercík, P ;
Wang, L ;
Verdü, EF ;
Mao, YK ;
Blennerhassett, P ;
Khan, WI ;
Kean, I ;
Tougas, G ;
Collins, SM .
GASTROENTEROLOGY, 2004, 127 (01) :179-187
[8]  
Cebra J J, 1998, Dev Immunol, V6, P13, DOI 10.1155/1998/68382
[9]   Activation of the mucosal immune system in irritable bowel syndrome [J].
Chadwick, VS ;
Chen, WX ;
Shu, DR ;
Paulus, B ;
Bethwaite, P ;
Tie, A ;
Wilson, I .
GASTROENTEROLOGY, 2002, 122 (07) :1778-1783
[10]   The putative role of inflammation in the irritable bowel syndrome [J].
Collins, SM ;
Piche, T ;
Rampal, P .
GUT, 2001, 49 (06) :743-745